Rockefeller Capital Management’s Outlook Therapeutics OTLK Stock Holding History
Bought
Maintained
Sold
Other funds holding OTLK
Rockefeller Capital Management's OTLK Position: Q3 2026 in Review
Rockefeller Capital Management increased its Outlook Therapeutics (OTLK) stake by 28% in Q3 2026, buying an estimated $1.67K and bringing the position to 8,000 shares worth $4.59K. The position accounts for ﹤0.01% of the portfolio, ranked #4404.
Rockefeller Capital Management first reported a position in OTLK in Q2 2026 and has held it in 2 quarters since. The position peaked at $9.9K in Q2 2026. 82 funds tracked by Wall St. Rank hold OTLK as of Q3 2026.
- Rockefeller Capital Management held 8,000 shares of Outlook Therapeutics worth $4.59K as of Q3 2026.
- Rockefeller Capital Management bought 1,750 Outlook Therapeutics shares in Q3 2026, an estimated $1.67K.
- Outlook Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #4404 holding.
- Rockefeller Capital Management first reported a position in Outlook Therapeutics in Q2 2026 and has held it in 2 quarters since.
- Rockefeller Capital Management's Outlook Therapeutics position peaked at $9.9K in Q2 2026.
- 82 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.